Life Sciences

41 to 50 of 146
  • Data protection concerns about the Fourth Money Laundering Directive Restricted access

    Article

    Last Reviewed: 31 December 2013 / Submitted: 31 December 2013

    The proposed Fourth Money Laundering Directive raises significant data protection concerns as it is not sufficiently clear about the nature of the personal data which firms may have to collect in order to comply. This article summarises the background to the Fourth Money Laundering Directive, the data protection issues relating to the proposed Directive, and the actions that the Commission proposes to take in order to deal with these concerns.

  • Whistleblowing in the life sciences sector upcoming developments Restricted access

    Article

    Last Reviewed: 05 January 2015 / Submitted: 29 November 2013

    A summary of whistleblowing in the life sciences sector - upcoming developments

  • Stay of English litigation pending outcome of EPO proceedings? Restricted access

    Article

    Submitted: 26 November 2013

    Court of Appeal Decision of 21 November 2013 in IPCom v HTC.

  • Resolution v Lundbeck: judicial bias Restricted access

    Article

    Submitted: 11 November 2013

    Lundbeck requested that Arnold J recuse himself because an expert witness in the case had been his university supervisor. In refusing the application Arnold J explained the rules relating to judicial bias.

  • Aventis Pharmaceuticals v OHIM Restricted access

    Article

    Submitted: 07 November 2013

    The EU General Court has ruled that the OHIM Opposition Division and Board of Appeal erred in finding a low degree of similarity between the CULTRA (fig) and SCULPTRA trade marks.

  • Patents and personalised medicines Restricted access

    Article

    Submitted: 07 November 2013

    A review of the patentability of personalised medicine patent claims in the UK and Europe.

  • Social media in medicine - a moving target Restricted access

    Article

    Submitted: 25 October 2013

    A discussion of the various approaches by EU Member States on how to police medical promotions regulations in the context of social media.

  • Transparency and access to clinical data: the national position Restricted access

    Article

    Submitted: 23 October 2013

    A discussion of the laws relating to disclosure of clinical trial data at EU Member State level.

  • The skinny label, generic drugs and second medical use patent claims Restricted access

    Article

    Submitted: 09 October 2013

    An analysis of issues relating to skinny labelling and the infringement of second medical use patent claims.

  • Episode 352: Opting-out of the UPC

    Video Podcast

    Submitted: 24 September 2013

    Gillian Johnson talks to Nicholas Fox about what European patentees should be considering with regard to opting-out their patents of the Unified Patents Court (UPC).

41 to 50 of 146